ESC 365 - Valve-in-valve TAVI regardless of risk profile - Discussion

ESC Premium Access

Valve-in-valve TAVI regardless of risk profile - Discussion

Session: Controversies in the treatment of aortic valve disease

Topic: Treatment

Event: ESC Congress 2019

Congress Presentation

Add to my library

5 more presentations in this session

Pure aortic regurgitation remains off-limits for TAVI - PRO

Speaker: Professor T. Folliguet (Creteil, FR)

Pure aortic regurgitation remains off-limits for TAVI - CON

Speaker: Doctor R. Makkar (Los Angeles, US)

Pure aortic regurgitation remains off-limits for TAVI - Discussion

Valve-in-valve TAVI regardless of risk profile - PRO

Speaker: Doctor D. Dvir (Jerusalem, IL)

Valve-in-valve TAVI regardless of risk profile - CON

Speaker: Professor G. Gerosa (Padua, IT)

Access the full session

Controversies in the treatment of aortic valve disease

Speakers: Professor T. Folliguet, Doctor R. Makkar, Doctor D. Dvir, Professor G. Gerosa

About the event

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources